Skip to content
Screener

DaVita DVA Cash & Equivalents

Cash & Equivalents at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
$28B-8.8%
Outset Medical, Inc. logo
Outset Medical, Inc.OM
$35.01M-11.5%
Baxter International logo
Baxter InternationalBAX
$2.02B-12.1%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$193.77M-2.5%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$2.11M+39.8%
iRadimed logo
iRadimedIRMD
$56.37M+12.0%

Other financials

Income statement

See full
Revenue$3.4B+6.0%
Operating income$481.9M+9.8%
Net income$197.5M+21.2%
EPS (diluted)$2.87+43.5%

Balance sheet

See full
Total debt$13.3B+6.7%
Total equity-$755.5M-183%
Total assets$17.5B+2.2%

Cash flow

See full
Operating cash flow$320.8M+78.2%
CapEx$102.0M-28.8%
Free cash flow$218.8M+495%

Valuation

See full
Market cap$12.04B+31.7%
Enterprise value$24.65B+15.5%
P/E15.4×+4.5×
P/S0.9×+0.2×

Profitability

See full
Operating margin15.1%-0.7pp
Net margin5.6%-1.0pp
FCF margin10.8%-2.8pp

Returns & leverage

See full
Return on equity159.1%+80.9pp
Debt / equity103.6×+92.8×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by DaVita in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: DaVita’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 5:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000927066-26-000062
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Payment of tax withholdings on net share settlements of equity awards(63,155)(30,214)
Contributions from noncontrolling interests4,0492,169
Purchases of noncontrolling interests(18,082)(5,378)
Net cash used in financing activities(213,343)(382,540)
Effect of exchange rate changes on cash, cash equivalents and restricted cash2599,417
Net decrease in cash, cash equivalents and restricted cash(31,344)(355,252)
Cash, cash equivalents and restricted cash at beginning of the year757,747879,825
Cash, cash equivalents and restricted cash at end of the period$726,403$524,573

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is DaVita's cash & equivalents?
DaVita (DVA) reported cash & equivalents of $726.4M in Q1 2026.
How has DaVita's cash & equivalents changed year-over-year?
DaVita's cash & equivalents increased by 38.5% year-over-year, from $524.57M to $726.4M.
What is the long-term trend for DaVita's cash & equivalents?
Over 5 years (2020 to 2025), DaVita's cash & equivalents has grown at a 8.6% compound annual growth rate (CAGR), from $501.79M to $757.75M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about DaVita's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude